European Medicines Agency’s CHMP Rejects Celgene’s Revlimid In Myelodysplastic Syndromes
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency reiterates negative opinion on Wyeth's Mylotarg for acute myeloid leukemia.